������ý

Artificial intelligence continues to be one of the most talked about business trends. Many of the AI technologies that health care and life sciences companies are adopting are largely untested from a legal perspective, creating gray areas that regulatory agencies are grappling with. AI innovations also offer opportunities for competitive advantage through the strategic management of intellectual property rights.

Telemedicine companies are preparing for heightened regulatory scrutiny of advertising on social media platforms while seeing an overall shift from direct-to-consumer to third-party reimbursement models. On the provider front, established health care systems are increasingly entering into joint ventures with technology-enabled health care platform startups to evolve and innovate.

Pharmaceutical companies are bracing for what could be a sea change in the “deference, supremacy, preemption” paradigm while cosmetics manufacturers are facing increased FDA regulatory requirements under the Modernization of Cosmetics Regulation Act of 2022. The FDA also continues to demonstrate a commitment to expanding diversity in clinical trials with a focus on the recruitment of diverse clinical trial participants.

��DZ����’s Health Care & Life Sciences Sector is comprised of 200+ attorneys with decades of collective in-house experience at health care providers and vendors, pharmaceutical and biotechnology firms, and key state and federal government agencies. Our attorneys have been deeply immersed in these industries, acquiring substantial technical and scientific knowledge through graduate degrees and ongoing training that enables us to provide forward-looking, practical solutions to our clients most pressing business challenges.

The 2024 Health Care & Life Sciences Top Trends Report includes the following articles.

• Health Care Litigation: Overview and Assessment of the Impact of Artificial Intelligence
• Litigation Trends: How Court Decisions Will Affect Pharmaceutical Manufacturers
• Balancing Innovation and Safety: FDA Regulation of AI in Medical Devices
• Intellectual Property Strategies for Digital Health AI Companies: Increasing Valuation and Creating Barriers for Competitors
• FDA and FTC Poised to Regulate Social Media Advertising of Drugs and Digital Health Services
• FDA Regulation of Cosmetics – The Beauty or the Beast
• Telemedicine Companies Increasingly Shift from Cash-Only Direct-to-Consumer Models to Third-Party Reimbursement
• Diversity in Clinical Trials
• Medicare Advantage Marketing Under Pressure
• 2024 Will Be a Critical Year for the 340B Drug Pricing Program
• Health Care Joint Ventures are Heating Up. Here’s What Providers Need to Know